MD Biosciences Blog

As an already fully functioning good laboratory practices (GLP) operation, MD Biosciences has recently achieved a new stage of value through CLIA certification for our high quality-testing services in the clinical and diagnostic arenas. CLIA or the Clinical Laboratory Improvements Amendments was put in place at the federal level to ensure a high level of laboratory testing. Therefore, clients can be assured that MD Biosciences meets these high quality standards and feel confident that their samples will be handled with the utmost technical and professional care to obtain reliable results.

The 2015 annual AMP meeting opened Novemeber 5^th in Austin TX, with a presentation by Dr Brian Druker titled “Imatinib as a Paradigm of Targeted Cancer Therapies.”  This year’s recipient of the AMP Award for Excellence in Molecular Diagnostics, Dr Druker highlighted the importance of identifying patients through biomarkers and matching therapies to the patient.  This theme continued through many of the presentations, posters and vendor exhibits the importance of providing physicians actionable results for patient care and therapeutics.  Molecular diagnostics are critical to any discussion on precision or personalized medicine.